Toll-like receptor (TLR)-8 agonists typified by the 2-alkylthiazolo[4,5-c]quinolin-4-amine (CL075) chemotype are uniquely potent in activating adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds could be promising candidate vaccine adjuvants, especially for neonatal vaccines. Alkylthiazoloquinolines with methyl, ethyl, propyl and butyl groups at C2 displayed comparable TLR8-agonistic potencies; activity diminished precipitously in the C2-pentyl compound, and higher homologues were inactive. The C2-butyl compound was unique in possessing substantial TLR7-agonistic activity. Analogues with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk. Virtually all modifications at C8 led to abrogation of agonistic activity. Alkylation on the C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups (other than acetyl) retained TLR8 agonistic activity, but were substantially less water-soluble. Immunization in rabbits with a model subunit antigen adjuvanted with the lead C2-butyl thiazoloquinoline showed enhancements of antigen-specific antibody titers.
Introduction
There can be no greater substantiation of Benjamin Franklin's adage, 'An ounce of prevention is better than a cure' than the resounding impact that vaccines have had in preventing morbidity and mortality due to infectious diseases. 1 Vaccines afford protection by the induction of immune responses, both humoral and cellular, specifically directed against the pathogen. Such adaptive immune responses are mobilized and amplified by engagement of the innate immune system, a phylogenetically and teleologically ancient system of host defense. [2] [3] [4] Unlike adaptive immunity, the initial innate immune responses rely on a limited number of germline-encoded pattern recognition receptors which recognize specific molecular patterns present in molecules that are broadly shared by pathogens but are sufficiently different so as to be distinguishable from host molecules. 5, 6 Innate immune afferent signals include those originating from Toll-like receptors (TLRs), as well as RIG-I-like receptors 7 and Nod-like receptors (NLRs). 8, 9 There are 10 functional TLRs encoded in the human genome, which are trans-membrane proteins with an extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1 receptor (TIR) domain. 6 The ligands for these receptors are highly conserved molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR11). 10 TLR1, -2, -4, -5, and -6 recognize extracellular stimuli, while TLR3, -7, -8 and -9 function within the endolysosomal compartment. 6 The activation of TLRs by their cognate ligands leads to production of inflammatory cytokines, and up-regulation of MHC molecules and co-stimulatory signals in antigenpresenting cells as well as activating natural killer (NK) cells (innate immune response), which leads to the priming and amplification of T-, and B-cell effector functions (adaptive immune responses). [11] [12] [13] [14] In recognition that the initial innate immune responses serve to marshal, focus, and amplify subsequent adaptive immune responses, 15, 16 there is considerable interest in utilizing TLR agonists as vaccine adjuvants. 17, 18 In contradistinction to early vaccines which used killed whole organisms, [19] [20] [21] [22] or attenuated live vaccines, [23] [24] [25] modern vaccines increasingly rely on subunit vaccines which have the distinct advantages of ease of production, quality control, and safety; however, such subunit antigens which are largely soluble proteins are poorly immunogenic, and require adjuvants to induce robust immune responses. Currently, the only TLR agonist approved by the FDA as an adjuvant is 3-O-desacyl-4′-monophosphoryl lipid A, (MPL), a TLR4 agonist derived from hydrolytic treatment of lipopolysaccharide isolated from Salmonella minnesota Re595. 26 We have recently begun exploring 27,28 a variety of TLR agonists with a view to identifying safe and potent vaccine adjuvants. The chemotypes that we have explored thus far include agonists of TLR2, [29] [30] [31] TLR7, [32] [33] [34] [35] [36] nucleotide oligomerization domain 1 (Nod1), 37 as well as C-C chemokine receptor type 1 (CCR1). 38 We now extend our investigations toward delineating structure-activity relationships in small-molecule agonistic ligands of TLR8 (typified by the thiazolo [4,5-c] quinolines) for the following reasons:
First, the thiazoloquinolines are of interest because like the imidazoquinolines, these compounds were identified in antiviral assays long before the discovery of the endosomal TLR7 and TLR8 receptors, [39] [40] [41] [42] [43] and other than the original landmark studies performed by investigators at 3M Pharmaceuticals, 44, 45 structure-activity relationships in the thiazoloquinoline chemotype remains poorly explored; qualitative assays for TNF-α and IFN-α induction in human blood were performed in initial studies by 3M as surrogate biomarkers of immunostimulation, and no data on TLR-7 and -8 specific agonistic activities exist in the literature.
Second, TLR8 agonists, both single-stranded RNA as well as small molecule imidazoquinoline ligands such as R-848 46 and thiazoloquinolines such as 3M-002 (CL075) 47, 48 appear uniquely potent in activating costimulatory responses in neonatal antigen-presenting cells (APCs), inducing robust production of the T helper 1 (Th1)-polarizing cytokines TNF-α and IL-12, which are not observed upon stimulation by TLR-2, -4, or -7 agonists. Such Th1-biasing compounds are of particular interest as candidate vaccine adjuvants in the newborn. 49 During the first few weeks of life, newborns rely almost entirely on maternal IgG antibodies acquired by passive transplacental passage, 50 and remain susceptible to a wide range of pathogens until early infancy. 51 Neonates and infants, in whom vaccines could -and perhaps should -have the greatest impact do not mount adequate adaptive immune responses, and therefore are most vulnerable; consequently, even the most efficacious vaccines that confer excellent protection in adults may fail to elicit strong immune responses in them. 52, 53 There is mounting evidence pointing to significant differences between adult and infant innate immune responses. 54 The neonatal immunophenotype is characterized by decreased production of both type I and type II interferons, Interleukin (IL)-12, IL-18, IL-23 and other proinflammatory cytokines such as Tumor Necrosis Factor-α (TNF-α), the preferential induction of memory B lymphocytes rather than immunoglobulin-secreting plasma cells, as well as a pronounced T-helper type 2 (Th2) skewing of T-cell responses. 51, 52, 55, 56 TLR8 agonists induce the production of IL-12, IL-18 and IFN-γ, and may therefore be of value in developing vaccines for the neonate.
Given the potential utility of TLR8 agonists as adjuvants for neonatal vaccines, it was of interest to explore SAR in the thiazoloquinolines (typified by CL075, 8c in Scheme 1). Our studies began with examining the optimal alkyl chain length at the C2 position. We found that the C2-alkyl thiazoloquinolines exhibit mixed TLR8/7 agonistic activities in primary reporter gene assays with the optimal chain length being butyl. We observed an unexpectedly strict length dependence with only the C2-butyl, but none of the other analogues, inducing IFN-α in human peripheral blood mononuclear cells (hPBMCs). Examination of analogues with branched alkyl groups at C2 suggested poor tolerance of terminal steric bulk. We noted, however that certain C2-branched analogues were substantially more TLR8-selective than their corresponding straight-chain analogues. Virtually all modifications at C8 led to abrogation of agonistic activity. Alkylation on the C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups (other than acetyl) retained activity.
Results and Discussion
In our previous work on the TLR7-active imidazoquinolines, we had observed a distinct relationship between C2-alkyl chain length and TLR7-agonistic potency, 33 and we therefore thought it logical to begin our SAR studies on the thiazoloquinolines by examining analogues with C2-alkyl groups of varying chain lengths. These analogues (8a-8h, Scheme 1) were synthesized in parallel from the 3-aminoquinolin-4-ol precursor 4, using the strategy described earlier. 33, 44 In primary screens using human TLR7 and TLR8-specific reporter gene assays, these analogues exhibited mixed TLR8/TLR7 agonism; the EC 50 values of 8c (CL075) were found to be 1.32 μM and 5.48 μM, in TLR8 and TLR7 assays, respectively (Fig. 1 , Table  1 ). As in our earlier SAR studies on the imidazoquinolines, 33 we observed a clear dependence of agonistic potency on the C2-alkyl chain length. The C2-methyl, -ethyl, andpropyl analogues (8a-8c) displayed comparable potencies in the hTLR8 and hTLR7 reporter gene assays (Fig. 1) . Maximal TLR8-agonistic potency was observed in the butyl analogue (8d). Increasing the chain length to pentyl (8e) led to attenuation of potency, and hgher homologues (8f-8h) showed abrogation of activity (Fig. 1, Table 1 ).
The C2-butyl analogue 8d appeared to exhibit substantially higher TLR7-agonistic potency than 8c (Figs. 1 and 3 ), suggesting that small variations at C2 could modulate TLR8 versus TLR7 specificity. The introduction of an isopropyl group at C2 (8i) led to an approximately ten-fold reduction in TLR8-agonistic potency (Table 1) , while the attenuation of its activity in TLR7-specific reporter gene assays was more modest (about two-fold). These results warranted the syntheses of several additional analogues of both 8c (C2-n-propyl) and 8d (C2-n-butyl) with branched alkyl groups at C2 (8j-8o, Scheme 1, Fig. 2 ). Additional methyl substitutions at ω as well as ω-1 positions were well tolerated in 8c derivatives (8j and 8n, respectively; Scheme 1, Fig. 2 ). On the other hand only the ω-1 methyl-substituted compound 8o was active in the 8d series, whereas the 8l congener with a terminal methyl substitution was entirely inactive. Both 8k and 8m bearing terminal trimethyl groups were also inactive, suggesting poor tolerance of terminal steric bulk in these compounds.
We also evaluated bioisosteric analogues 8p and 8q (Scheme 1) with terminal trifluoromethyl groups. A decrease in potency at TLR8 was observed in the longer homologue (8q). We noted that, in general, analogues with branched C2-alkyl groups of optimal chain length and bulk (such as 8j, 8n, and 8o) are substantially more TLR8-selective than their corresponding straight-chain analogues (Fig. 2) .
However, in secondary cytokine induction screens using human PBMCs, the branched-chain analogues behave differently in that they were neither as potent as their straight-chain parent compounds (Fig. 3) , nor did they show enhanced IL-12, IL-18, and IFN-γ production (data not shown) as would be expected for TLR8-selective compounds. 47, 48 We do not yet understand the basis of attenuated activity of the C2-branched analogues, and we are currently exploring whether differential plasma protein binding behavior of these compounds could be contributory. 57 Previous reports on the thiazoloquinolines 44, 45, 58 had been performed largely on the C7 position, and C8 and C4 analogues remain unexplored. We therefore first examined substituents on the quinoline at the C8 position of 8c (CL075). Electrophilic substitution on the quinoline ring selectively afforded the 8-nitro analogue 9 (Scheme 2), and the 8-bromo analogue 14 (Scheme 4), both of which were inactive. The 8-amino (10) and 8-azido (11) analogues were obtained from 9 (Scheme 2). Compound 10 showed attenuated activity relative to 8c, and 11 was inactive. The triazole derivatives 12a-g were synthesized from 11 (Scheme 2) using conventional copper-catalyzed 'click' chemistry; of these analogues, the triazolo analogue 12e displayed feeble, but selective TLR8 agonism (Table 1) . Selective C8 N-alkylation and N-acylation of the 8-amino analogue 10 provided analogues 13a and 13b (Scheme 3), both of which were inactive (Table 1) .
Next, the C4-amine of 8c was alkylated or acylated, yielding analogues 15a-15l (Scheme 5). The C4-N-alkylated compounds 15a and 15b were devoid of any agonistic activity, while some, but not all of the C4-N-acylated derivatives with short acyl groups were found to be active. Specifically, the formyl (15d), and butyryl (15f) analogues, but not the acetyl (15e) compounds were active.
Although weaker in potency than the parent compound 8c, these C4-N-acyl derivatives exhibited a pronounced specificity for TLR8 (Table 1) . We observed an unusual discontinuity in the activity profiles in this homologous series of compounds. The TLR8-agonistic potency of the formyl analogue 15d was comparable to that of 8c. The acetyl analogue 15e, however, was virtually inactive, but activity was partially restored in the butyryl compound 15f (Fig. 4A) , while higher homologues (15g and 15h) were inactive (Table 1) .
Cytokine induction profiles in hPBMCs mirrored these findings with a near-complete loss of activity for the acetyl compound 15d (Fig. 5A ).
Our provisional interpretation that a strict length requirement exists for the acyl substituents on the C4-amine was borne out in compounds 15j-15l (azidoacetamide, azidopropionamide and pentynamide analogues, respectively) which displayed weak, TLR8-selective agonistic activity (Table 1) . Aromatic amides at this position appear not to be tolerated, since the benzamide analogue 15i was entirely inactive.
A series of carbamates (15m-15p), and sulfonamides (15r-sulfonamides (15r-15v) were also synthesized (Scheme 5). The carbamate derivatives showed very weak activity in primary reporter gene assays, while the sulfonamide analogues were completely inactive (Table 1) . Several other analogs including urea (15q; Scheme 5), phosphoramidate (15w; Scheme 5) and guanidine (17; Scheme 6) functional groups at C4 were also examined, but were found to be inactive.
The peculiar SAR, with only the acetamide analogue (15e) showing loss of activity was unexpected and, desiring to confirm this pattern, we also synthesized select amide analogues of 8d (18a-18c, formamide, acetamide, and butyramide derivatives, respectively; Scheme 7). As with the 8c derivatives, a virtually identical pattern was observed, with a selective loss of activity for the acetamide analogue 18b (Fig. 4B, Fig. 5B , Table 1 ).
Our studies aimed at delinating structure-activity relationships in the thiazoloquinolines have led to selecting 8d as a lead thiazoloquinoline. This compound distinguishes itself from its closely-related congener, 8c (CL075) in possessing a more balanced TLR8/TLR7-agonistic properties. Virtually all other analogues were either of lower potency, exhibited very poor aqueous solubility (such as the amide analogues 15d and 18a), or despite apparent greater TLR8 selectivity in primary screens, were either unremarkable in secondary screens employing human PBMCs, or inferior in their cytokine induction profiles (8j, 8n, and 8o, for instance). We therefore elected to directly evaluate the adjuvantic properties of 8d, and benchmark it against 8c (CL075), noting that adjuvantic properties for the thiazoloquinolines have not been previously reported in the literature. In light of the fact that murine TLR8 is thought to be functionally inactive, [59] [60] [61] we chose to examine the adjuvantic activities of 8c, 8d directly in a rabbit model using bovine α-lactalbumin as a model subunit vaccine antigen, which is a small (14 kDa), soluble protein which we have adopted as our test-antigen in ongoing humoral and cellular immune response assays. 35 We found that both 8c and 8d were adjuvantic in evoking high antigen-specific IgG titers (Fig. 6) . Importantly, no evidence of local or systemic toxicity was apparent in any of the cohorts. The data suggests that 8d, with its dual TLR8/TLR7-agonistic properties, elicits adjuvanticity with greater consistency and uniformity, as evidenced by narrower confidence intervals of antibody titers (Fig. 6 ).
Conclusions
TLR8 agonists are thought to be uniquely potent in activating adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, and may be promising candidate vaccine adjuvants, especially for neonatal vaccines. Thiazoloquinoline analogues with methyl, ethyl, propyl and butyl groups at C2 displayed comparable TLR8-agonistic potencies; however, the C2-butyl compound 8d was unique in possessing substantial TLR7-agonistic activity. Analogues with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk. C4-N-acyl analogues with short acyl groups (other than acetyl) retained TLR8 agonistic activity, but were substantially less water-soluble. Immunization in rabbits with a model subunit antigen adjuvanted with the most potent TLR8 agonist showed dramatic enhancements of antigen-specific antibody titers.
Experimental

Materials and Equipment
All of the solvents and reagents used were obtained commercially and used as such unless noted otherwise. Moisture-or air-sensitive reactions were conducted under nitrogen atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced pressure using standard rotary evaporators. Flash column chromatography was carried out using RediSep Rf 'Gold' high performance silica columns on CombiFlash Rf instrument unless otherwise mentioned, while thin-layer chromatography was carried out on silica gel (200 μm) CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed to be greater than 98% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 μm analytical reverse phase C18 column with H 2 O-isopropanol or H 2 O-CH 3 CN gradients and either an Agilent ESI-TOF mass spectrometer (mass accuracy of 20 ppm) or an Agilent 6520 ESI-QTOF mass spectrometer (mass accuracy of <10 ppm) operating in the positive ion (or negative ion, as appropriate) acquisition mode.
Synthesis of compound 2: 2-(2-nitroethylideneamino)benzoic acid
Nitromethane (4.32 mL, 80 mmol) was added dropwise to a solution of NaOH (9.6 g, 250 mmol) in water (10 mL), at 0 °C. The mixture was then warmed to 40 °C and nitromethane (4.32 mL, 80 mmol) was again added slowly at 40-45 °C. The temperature was maintained until a clear solution was obtained. The reaction mixture was then heated to 55 °C for 2-5 minutes, cooled to 30 °C, poured onto crushed ice and acidified with conc. HCl (11 mL). The resultant solution of methazoic acid was added immediately to a filtered solution of anthranilic acid 1 (10 g, 73 mmol) and conc. HCl (3.3 mL) in water (75 mL). The reaction mixture was allowed to stand at room temperature for 12 h. After filtration, the residue obtained was washed with water, and dried to yield compound 2 (12.94 g, 85% 
Synthesis of compound 4: 3-aminoquinolin-4-ol
To a solution of compound 3 (1.89 g, 9.93 mmol) in DMF (25 mL), was added 5% Pt on carbon (20%, 0.38g). The reaction mixture was allowed to react in a Parr hydrogenation apparatus at 60 psi H 2 pressure for 3.5 h with vigorous shaking. The reaction mixture was filtered through celite with several washes of methanol. The filtrate was concentrated by evaporation to get 4-amino-3-nitroquinoline (1.5g, 94%). 1 H NMR (500 MHz, MeOD) δ 
Synthesis of compound 5a: N-(4-hydroxyquinolin-3-yl)acetamide
Compound 4 (200 mg, 1.25 mmol) was dissolved in a mixture of CH 2 Cl 2 (20 mL) and DMF (2 mL) and stirred at room temperature for 5 min. Acetyl chloride (133 μL, 1.875 mmol) was added to the stirring reaction mixture at 0 °C and the solution was allowed to react for 1.5 h. Solvents were removed and the crude residue was purified using silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to obtain the compound 5a (106 mg, 42% Compounds 5b-5q were synthesized similarly as compound 5a. 
Synthesis of compound 6a: 2-methylthiazolo[4,5-c]quinoline
To a solution of compound 5a (100 mg, 0.49 mmol) in pyridine (10 mL), was added phosphorous pentasulfide (109 mg, 0.49 mmol) and reaction mixture was refluxed for 2 h. The resulting solution was cooled to room temperature and pyridine was removed under reduced pressure. The residue was dissolved in water and pH was adjusted to 8 with saturated sodium bicarbonate solution and extracted in ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to afford compound 6a (64 mg, 65% Compounds 6b-6q were synthesized similarly as compound 6a.
6b: 2-ethylthiazolo[4,5-c]quinoline
(90 mg, 70% 
Synthesis of compound 8a: 2-methylthiazolo[4,5-c]quinolin-4-amine
Compound 7a (50 mg, 0.23 mmol) was dissolved in anhydrous CH 2 Cl 2 (5 mL). Benzoyl isocyanate (68 mg, 0.46 mmol) was added to the reaction mixture and refluxed for 30 min. The solvent was then removed under vacuum and the residue was dissolved in anhydrous methanol (5 mL). Excess of sodium methoxide was added and the reaction mixture was refluxed for 2 h. After evaporating solvents under reduced pressure, the crude residue was purified using silica gel column chromatography (7% MeOH/CH 2 Cl 2 ) to obtain compound 8a as a white solid (41 mg, 82% Compounds 8b-8q were synthesized similarly as compound 8a.
8b: 2-ethylthiazolo[4,5-c]quinolin-4-amine
White solid (36 mg, 47% 
8c: 2-propylthiazolo[4,5-c]quinolin-4-amine
White solid (450 mg, 90% 
8o: (S)-2-(2-methylbutyl)thiazolo[4,5-c]quinolin-4-amine
White solid (46 mg, 77% 
Synthesis of compound 9: 8-nitro-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (200 mg, 0.82 mmol) in H 2 SO 4 (0.5 mL), was added HNO 3 (0.5 mL) and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was neutralized with 1N NaOH and extracted with EtOAc (3 × 15 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude residue was purified using silica gel column chromatography (5% MeOH/ CH 2 Cl 2 ) to obtain compound 9 as yellow solid (171 mg, 72% 
Synthesis of compound 10: 2-propylthiazolo[4,5-c]quinoline-4,8-diamine
To a stirred solution of compound 9 (200 mg, 0.69 mmol) in methanol (5 mL), were added zinc dust (453 mg, 6.94 mmol) and ammonium formate (437 mg, 6.94 mmol), and the reaction mixture stirred at room temperature for 30 min. The reaction mixture was then filtered through celite, the filtrate concentrated under reduced pressure, and purified over silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to afford compound 10 as a yellow solid (185 mg, 88% 
Synthesis of compound 11: 8-azido-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 10 (25 mg, 0.096 mmol) in a 1:1 mixture of acetic acid and water (2 mL), was added sodium nitrite (20 mg, 0.29 mmol) and the reaction mixture was stirred at room temperature for 1 h. Sodium azide (18.8 mg, 0.29 mmol) was then added to the reaction mixture and stirred for additional 1 h. The reaction mixture was neutralized with 1N NaOH and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude compound was purified on silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 11 as a brown solid (18 mg, 67%). 
Synthesis of compound 12a: 2-(1-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)-1H-1,2,3-triazol-4-yl)propan-2-ol
To a stirred solution of compound 11 (12 mg, 0.042 mmol) in THF (1 mL), were added CuSO 4 .5H 2 O (1.3 mg, 0.005 mmol, in 0.5 mL water), sodium ascorbate (2.1 mg, 0.010 mmol, in 0.5 mL water), 2-methylbut-3-yn-2-ol (8.4 μL, 0.084 mmol), and the reaction mixture stirred at room temperature for 1 h. The reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude residue was purified using silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to obtain compound 11 as a white solid (14 mg, 92% 
Synthesis of compound 12g: 2-propyl-8-(1H-1,2,3-triazol-1-yl)thiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 12f (20 mg, 0.0.52 mmol) in THF (1 mL) was added TBAF (20 mg, 0.078 mmol), and the reaction mixture was stirred at room temperature for 10 h. The reaction mixture was then diluted with water and extracted with EtOAc (3 × 10 mL). The organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude material purified using silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 12g as a white solid (14 mg, 87% 
Synthesis of compound 13b: N-(4-amino-2-propylthiazolo[4,5-c]quinolin-8-yl)butyramide
To a stirred solution of compound 10 (20 mg, 0.077 mmol) in CH 2 Cl 2 (2 mL) were added triethylamine (30 μL, 0.164 mmol) and butyryl chloride (8.7 μL, 0.082); the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was then diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude compound was purified using silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to furnish compound 13b as a white solid (22 mg, 87% 
Synthesis of compound 14: 8-bromo-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in CH 3 CN (1 mL) were added N-bromosuccinimide (44 mg, 0.246 mmol), ammonium acetate (1.6 mg, 0.02 mmol) and the reaction mixture stirred at room temperature for 12 h. The reaction mixture was then diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude material was purified using silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 14 as a white solid (40 mg, 67% 
Synthesis of compound 15a: N-butyl-2-propylthiazolo[4,5-c]quinolin-4-amine
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in THF (1 mL) were added sodium hydride (10 mg, 0.41 mmol) and 1-iodobutane (35 μL, 0.308 mmol), the resulting mixture was stirred at room temperature for 6 h. The reaction mixture was then diluted with water and extracted with CH 2 Cl 2 (3 × 10 mL). The organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude compound was purified using silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 15a (45 mg, 70% 
Synthesis of compound 15d: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)formamide
To a stirred solution of compound 8c (50 mg, 0.205 mmol) in 1,4-dioxane (1 mL) were added 2,2,2-trifluoroethylformate (60 μL, 0.616 mmol) and triethylamine (86 μL, 0.616 mmol). The resulting mixture was stirred at 80 °C for 12 h. The reaction mixture was then diluted with water and extracted with CH 2 Cl 2 (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude compound was purified using silica gel column chromatography (3% MeOH/CH 2 Cl 2 ) to furnish compound 15c as a white solid (26 mg, 46% 
Synthesis of compound 15e: N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide
To a stirred solution of compound 8c (20 mg, 0.082 mmol) in pyridine (1 mL) was added acetyl chloride (5.8 μL, 0.082 mmol), the resulting mixture was stirred at room temperature for 1 h. 
Synthesis of compound 15j: 2-azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)acetamide
To a stirred solution of 2-azidoacetic acid (18.6 mg, 0.123 mmol) in DMF (1 mL) were added triethylamine (23 μL, 0.164 mmol) and HBTU (46.6 mg, 0.123 mmol), and the resulting mixture was stirred at room temperature for 15 min. Compound 8c (20 mg, 0.082 mmol) was then added, and stirring continued for 4 h. The reaction mixture was diluted with water and extracted with CH 2 Cl 2 (3 × 10 mL). The organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 15j as a white solid (50 mg, 96% Compounds 15k-15l were synthesized similarly as compound 15j.
15k: 3-azido-N-(2-propylthiazolo[4,5-c]quinolin-4-yl)propanamide
White solid (59 mg, 85% 
Synthesis of compound 15m: methyl (2-propylthiazolo[4,5-c]quinolin-4-yl)carbamate
To a stirred solution of 8c (50 mg, 0.205 mmol) in CH 2 Cl 2 (2 mL) were added triethylamine (57 μL, 0.410 mmol) and methyl chloroformate (32 μL, 0.3075 mmol), and the resulting mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with water and extracted with CH 2 Cl 2 (3 × 10 mL). The organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude residue was purified by silica gel column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain compound 15m (58 Compounds 15n-15p were synthesized similarly as compound 15m. TLR8 and TLR7 agonistic potencies of the C2-alkyl thiazoloquinoline homologues. Data points represent means and standard deviations of EC 50 values derived from dose-response profiles and are computed on quadruplicates. TLR8-and TLR7-specific NF-κB induction profiles of branched-chain and trifluoromethyl analogues of 8c and 8d. Means and SD obtained from quadruplicate samples are shown. EC 50 values of proinflammatory cytokine induction in human PBMCs by analogues of 8c and 8d. Representative data from three independent experiments are shown. Box-plots of anti-bovine α-lactalbumin IgG titers in cohorts of three rabbits immunized with α-lactalbumin adjuvanted with either 8c or 8d. Means and medians of titers are represented by □ and -symbols within the box, respectively, and the X symbols indicate the 1% and 99% percentile values.
Scheme 2.
Modification at the C8 position. Reagents: (i) HNO 3 Syntheses of C4 N-alkyl and N-acyl analogues of 8d. Reagents: (i) 2,2,2-trifluoroethylformate, Et 3 N; For 18a; RCOCl, pyridine for 18b and 18c. Table 1 EC 50 values of thiazoloquinolines in human TLR8-and TLR7-specific reporter gene assays.
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